Cargando…

Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients

BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). W...

Descripción completa

Detalles Bibliográficos
Autores principales: Penel, Nicolas, Negrier, Sylvie, Ray-Coquard, Isabelle, Ferte, Charles, Devos, Patrick, Hollebecque, Antoine, Sawyer, Michael B., Adenis, Antoine, Seve, Pascal
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715134/
https://www.ncbi.nlm.nih.gov/pubmed/19649260
http://dx.doi.org/10.1371/journal.pone.0006483
_version_ 1782169749481848832
author Penel, Nicolas
Negrier, Sylvie
Ray-Coquard, Isabelle
Ferte, Charles
Devos, Patrick
Hollebecque, Antoine
Sawyer, Michael B.
Adenis, Antoine
Seve, Pascal
author_facet Penel, Nicolas
Negrier, Sylvie
Ray-Coquard, Isabelle
Ferte, Charles
Devos, Patrick
Hollebecque, Antoine
Sawyer, Michael B.
Adenis, Antoine
Seve, Pascal
author_sort Penel, Nicolas
collection PubMed
description BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4). RESULTS: The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5×the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0–1], 2 and [3]–[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values. CONCLUSIONS: We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy.
format Text
id pubmed-2715134
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27151342009-08-03 Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients Penel, Nicolas Negrier, Sylvie Ray-Coquard, Isabelle Ferte, Charles Devos, Patrick Hollebecque, Antoine Sawyer, Michael B. Adenis, Antoine Seve, Pascal PLoS One Research Article BACKGROUND: We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients. METHODS: Predictors have been identified by univariate and then logistic regression analysis in a single-center cohort comprising 429 patients (development cohort). We identified four predictors that produced a predictive score that has been applied to an independent multi-institutional cohort of 409 patients (validation cohort). The score was the sum of predictors for each patient (0 to 4). RESULTS: The 90-day-mortality-rate was 33 and 26% in both cohorts. Multivariate analysis has identified 4 predictors for 90-day-mortality: performance status>1 (OR = 3.03, p = 0.001), at least one co-morbidity requiring treatment (OR = 2.68, p = 0.004), LDH>1.5×the upper limit of normal (OR = 2.88, p = 0.007) and low albumin or protein levels (OR = 3.05, p = 0.007). In the development cohort, 90-day-mortality-rates were 12.5%, 32% and 64% when the score was [0–1], 2 and [3]–[4], respectively. In the validation cohort, risks were 13%, 25% and 62% according to the same score values. CONCLUSIONS: We have validated a score that is easily calculated at the beside that estimates the 90-days mortality rate in non-specific CUP patients. This could be helpful to identify patients who would be better served with palliative care rather than aggressive chemotherapy. Public Library of Science 2009-08-03 /pmc/articles/PMC2715134/ /pubmed/19649260 http://dx.doi.org/10.1371/journal.pone.0006483 Text en Penel et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Penel, Nicolas
Negrier, Sylvie
Ray-Coquard, Isabelle
Ferte, Charles
Devos, Patrick
Hollebecque, Antoine
Sawyer, Michael B.
Adenis, Antoine
Seve, Pascal
Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title_full Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title_fullStr Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title_full_unstemmed Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title_short Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
title_sort development and validation of a bedside score to predict early death in cancer of unknown primary patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715134/
https://www.ncbi.nlm.nih.gov/pubmed/19649260
http://dx.doi.org/10.1371/journal.pone.0006483
work_keys_str_mv AT penelnicolas developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT negriersylvie developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT raycoquardisabelle developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT fertecharles developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT devospatrick developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT hollebecqueantoine developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT sawyermichaelb developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT adenisantoine developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients
AT sevepascal developmentandvalidationofabedsidescoretopredictearlydeathincancerofunknownprimarypatients